3/10
08:03 am
alms
Alumis Inc. (NASDAQ: ALMS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
Low
Report
Alumis Inc. (NASDAQ: ALMS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
3/10
08:00 am
alms
Alumis to Present at Leerink's 2025 Global Healthcare Conference
Low
Report
Alumis to Present at Leerink's 2025 Global Healthcare Conference
3/8
09:00 am
alms
Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis
Medium
Report
Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis
3/4
09:57 am
alms
Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger [Yahoo! Finance]
Low
Report
Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger [Yahoo! Finance]
3/4
09:01 am
alms
Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger
Medium
Report
Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger
3/3
08:10 am
alms
Alumis Inc. (NASDAQ: ALMS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
Low
Report
Alumis Inc. (NASDAQ: ALMS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
2/28
10:53 am
alms
Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout [Yahoo! Finance]
Low
Report
Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout [Yahoo! Finance]
2/28
09:08 am
alms
Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout
Medium
Report
Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout
2/27
04:15 pm
alms
Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases
Low
Report
Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases
2/10
05:50 pm
alms
Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
Low
Report
Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
2/10
04:45 pm
alms
Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
Low
Report
Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
2/7
03:22 pm
alms
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.
Low
Report
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.
2/7
08:28 am
alms
Alumis Inc. (NASDAQ: ALMS) had its price target lowered by analysts at HC Wainwright from $26.00 to $19.00. They now have a "buy" rating on the stock.
Medium
Report
Alumis Inc. (NASDAQ: ALMS) had its price target lowered by analysts at HC Wainwright from $26.00 to $19.00. They now have a "buy" rating on the stock.
2/6
09:50 pm
alms
ALMS Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Alumis Inc. is Fair to Shareholders
Low
Report
ALMS Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Alumis Inc. is Fair to Shareholders
2/6
04:15 pm
alms
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
High
Report
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
1/30
09:05 am
alms
Alumis Inc. (NASDAQ: ALMS) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $32.00 price target on the stock.
Low
Report
Alumis Inc. (NASDAQ: ALMS) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $32.00 price target on the stock.
1/28
08:00 am
alms
Alumis Strengthens Leadership Team with Key Appointments
Low
Report
Alumis Strengthens Leadership Team with Key Appointments
1/6
08:14 am
alms
Alumis Inc. (NASDAQ: ALMS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $26.00 price target on the stock.
High
Report
Alumis Inc. (NASDAQ: ALMS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $26.00 price target on the stock.
12/28
08:54 am
alms
Owning 32% shares,hedge funds owners seem interested in Alumis Inc. (NASDAQ:ALMS), [Yahoo! Finance]
Medium
Report
Owning 32% shares,hedge funds owners seem interested in Alumis Inc. (NASDAQ:ALMS), [Yahoo! Finance]
12/20
08:19 am
alms
Alumis Inc. (NASDAQ: ALMS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $26.00 price target on the stock.
Medium
Report
Alumis Inc. (NASDAQ: ALMS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $26.00 price target on the stock.
12/19
08:07 am
alms
Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005 [Yahoo! Finance]
Low
Report
Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005 [Yahoo! Finance]
12/19
08:00 am
alms
Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005
Low
Report
Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005